CMC for Biologicals

Steffen Gross has extensive experience in molecular and cell biology. Mr. Gross joined the Paul-Ehrlich Institute in 2005 and became Head of the Section monoclonal and polyclonal antibodies in 2012. Due to re-structure of the section he became Head of Section Quality and Non-clinical Evaluation of Antibody therapeutics" in 2022. He is involved in the assessment of the quality and preclinical issues for marketing authorization applications, scientific advices and clinical trial applications. Until 2012 Mr. Gross was laboratory head of the section monoclonal and polyclonal antibodies and involved in testing of immunoglobulins, immunsera and monoclonal antibodies. Before joining the Paul-Ehrlich Institute he worked in the Netherland for three years as a postdoc. During this time he had been working several months at the National Institute of Health in Bethesda. After his return to Germany in 2001 he became a research group leader at the University of Frankfurt.

Since August 2024, Dr Jandke has been serving as an independent consultant. Prior to that, he worked at Miltenyi from 2019, where he held responsibility for Regulatory Affairs across the European Union. Before his tenure at Miltenyi Biomedicine, Michael held various leadership roles within innovative healthcare companies, focusing on areas such as somatic cell-based medicinal products (sCBMP), tissue-engineered products (TEP), and gene therapeutics, as well as in the generic pharmaceutical sector. Dr Jandke studied Pharmacy at Humboldt University in Berlin and earned a Doctorate in Molecular Medicine from the same institution.

Keine ausführliche englische Beschreibung vorhanden